The prognostic value of amyloid imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 7, 2012, Pages 1207-1219

  Gelosa, Giorgio ^a,b   Brooks, David J ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease (AD); Amyloid imaging; Mild cognitive impairment (MCI); Pittsburgh Compound B (PiB); Positron emission tomography (PET)

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; AV 1; AV 45; AZD 2184; AZD 2184 C 11; AZD 4694; AZD 4694 F 18; BF 227; BF 227 C 11; CARBON 11; FDDNP F 18; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GE 067; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PITTSBURGH COMPOUND B; SB 13; SB 13 C 11; TRACER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTERIOR CINGULATE; BINDING AFFINITY; BRAIN ATROPHY; COGNITION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG BINDING; DRUG DISTRIBUTION; DRUG RETENTION; DRUG SAFETY; DRUG UPTAKE; FOLLOW UP; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; HIPPOCAMPUS ATROPHY; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY PROGRESSIVE APHASIA; PROGNOSIS; REVIEW;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; HUMANS; MILD COGNITIVE IMPAIRMENT; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; STILBENES; THIAZOLES;

EID: 84862705994     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2108-x     Document Type: Review

References (89)

1. S Gauthier B Reisberg M Zaudig RC Petersen K Ritchie K Broich, et al. 2006 Mild cognitive impairment Lancet 367 1262 1270 16631882 10.1016/S0140-6736(06)68542-5
2. T Crook H Bahar A Sudilovsky 1987 Age-associated memory impairment: diagnostic criteria and treatment strategies Int J Neurol 21-22 73 82 2980693
3. EM Ebly DB Hogan IM Parhad 1995 Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging Arch Neurol 52 612 619 7763211 10.1001/archneur.1995.00540300086018 1:STN:280:DyaK2M3otlCqsA%3D%3D
4. R Levy 1994 Aging-associated cognitive decline. Working party of the International Psychogeriatric Association in collaboration with the World Health Organization Int Psychogeriatr 6 63 68 8054494 10.1017/S1041610294001626 1:STN:280:DyaK2czjtFGksA%3D%3D
5. RC Petersen JE Parisi DW Dickson KA Johnson DS Knopman BF Boeve, et al. 2006 Neuropathologic features of amnestic mild cognitive impairment Arch Neurol 63 665 672 16682536 10.1001/archneur.63.5.665
6. RC Petersen 2004 Mild cognitive impairment as a diagnostic entity J Int Med 256 183 194 10.1111/j.1365-2796.2004.01388.x 1:STN:280: DC%2BD2cvhvFCkug%3D%3D
7. RC Petersen GE Smith SC Waring RJ Ivnik EG Tangalos E Kokmen 1999 Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 303 308 10190820 10.1001/archneur.56.3.303 1:STN:280:DyaK1M3gsFSqtw%3D%3D
8. MP Mattson 2004 Pathways towards and away from Alzheimer's disease Nature 430 631 639 15295589 10.1038/nature02621 1:CAS:528:DC%2BD2cXmt1Gis7o%3D
9. A Lim D Tsuang W Kukull D Nochlin J Leverenz W McCormick, et al. 1999 Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series J Am Geriatr Soc 47 564 569 10323650 1:STN:280:DyaK1M3lsFamsg%3D%3D
10. H Petrovitch LR White GW Ross SC Steinhorn CY Li KH Masaki, et al. 2001 Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study Neurology 57 226 234 11468306 10.1212/WNL.57.2.226 1:STN:280:DC%2BD38%2Fis1ajtg%3D%3D
11. AM Kazee TA Eskin LW Lapham KR Gabriel KD McDaniel RW Hamill 1993 Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria Alzheimer Dis Assoc Disord 7 152 164 8217089 10.1097/00002093-199307030-00004 1:STN:280:DyaK2c%2FjtV2hug%3D%3D
12. AR Varma JS Snowden JJ Lloyd PR Talbot DM Mann D Neary 1999 Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia J Neurol Neurosurg Psychiatry 66 184 188 10071097 10.1136/jnnp.66.2.184 1:STN:280:DyaK1M7mvVKmtw%3D%3D
13. RC Petersen GE Smith SC Waring RJ Ivnik E Kokmen EG Tangelos 1997 Aging, memory, and mild cognitive impairment Int Psychogeriatr 9 Suppl 1 65 69 9447429 10.1017/S1041610297004717
14. PJ Visser P Scheltens FR Verhey 2005 Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 76 1348 1354 16170074 10.1136/jnnp.2004.047720 1:STN:280:DC%2BD2Mvpslyisg%3D%3D
15. CR Jack Jr MS Albert DS Knopman GM McKhann RA Sperling MC Carrillo, et al. 2011 Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 257 262 21514247 10.1016/j.jalz.2011.03. 004
16. CR Jack Jr DS Knopman WJ Jagust LM Shaw PS Aisen MW Weiner, et al. 2010 Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 119 128 20083042 10.1016/S1474-4422(09)70299-6 1:CAS:528:DC%2BC3cXhtFeru74%3D
17. EC Mormino JT Kluth CM Madison GD Rabinovici SL Baker BL Miller, et al. 2009 Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects Brain J Neurol 132 1310 1323 10.1093/brain/awn320 1:STN:280:DC%2BD1MzisVKitg%3D%3D
18. RJ Perrin AM Fagan DM Holtzman 2009 Multimodal techniques for diagnosis and prognosis of Alzheimer's disease Nature 461 916 922 19829371 10.1038/nature08538 1:CAS:528:DC%2BD1MXht1KntLvO
19. A Lockhart 2006 Imaging Alzheimer's disease pathology: one target, many ligands Drug Discov Today 11 1093 1099 17129828 10.1016/j.drudis.2006.10.008 1:CAS:528:DC%2BD28Xht1eqtb%2FL
20. PW Thompson A Lockhart 2009 Monitoring the amyloid beta-peptide in vivo - caveat emptor Drug Discov Today 14 241 251 19135168 10.1016/j.drudis.2008.12. 004 1:CAS:528:DC%2BD1MXjt1Shtro%3D
21. CR Jack Jr VJ Lowe SD Weigand HJ Wiste ML Senjem DS Knopman, et al. 2009 Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain J Neurol 132 1355 1365 10.1093/brain/awp062
22. RA Sperling PS Aisen LA Beckett DA Bennett S Craft AM Fagan, et al. 2011 Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 280 92 21514248 10.1016/j.jalz.2011.03.003
23. PW Thompson L Ye JL Morgenstern L Sue TG Beach DJ Judd, et al. 2009 Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies J Neurochem 109 623 630 19226369 10.1111/j.1471-4159.2009. 05996.x 1:CAS:528:DC%2BD1MXksVKnsro%3D
24. MD Ikonomovic WE Klunk EE Abrahamson CA Mathis JC Price ND Tsopelas, et al. 2008 Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain J Neurol 131 1630 1645 10.1093/brain/awn016
25. A Lockhart JR Lamb T Osredkar LI Sue JN Joyce L Ye, et al. 2007 PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis Brain J Neurol 130 2607 2615 10.1093/brain/awm191 1:STN:280:DC%2BD2srnsV2mug%3D%3D
26. P Edison HA Archer R Hinz A Hammers N Pavese YF Tai, et al. 2007 Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study Neurology 68 501 508 17065593 10.1212/01.wnl.0000244749.20056.d4 1:STN:280:DC%2BD2s%2FpsFymsA%3D%3D
27. WE Klunk H Engler A Nordberg Y Wang G Blomqvist DP Holt, et al. 2004 Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 306 319 14991808 10.1002/ana.20009 1:CAS:528:DC%2BD2cXisFKntb8%3D
28. H Braak E Braak 1991 Neuropathological stageing of Alzheimer-related changes Acta Neuropathol 82 239 259 1759558 10.1007/BF00308809 1:STN:280:DyaK387gtFOiug%3D%3D
29. MM Svedberg H Hall E Hellstrom-Lindahl S Estrada Z Guan A Nordberg, et al. 2009 [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients Neurochem Int 54 347 357 19162107 10.1016/j.neuint.2008.12.016 1:CAS:528:DC%2BD1MXivVGltLY%3D
30. A Forsberg H Engler O Almkvist G Blomquist G Hagman A Wall, et al. 2008 PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 1456 1465 17499392 10.1016/j.neurobiolaging.2007.03.029 1:CAS:528:DC%2BD1cXhtVSjsr%2FI
31. NM Kemppainen S Aalto IA Wilson K Nagren S Helin A Bruck, et al. 2007 PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment Neurology 68 1603 1606 17485647 10.1212/01.wnl.0000260969.94695.56 1:CAS:528:DC%2BD2sXkvVWks70%3D
32. A Okello P Edison HA Archer FE Turkheimer J Kennedy R Bullock, et al. 2009 Microglial activation and amyloid deposition in mild cognitive impairment: a PET study Neurology 72 56 62 19122031 10.1212/01.wnl.0000338622.27876.0d 1:CAS:528:DC%2BD1cXhsFakur%2FE
33. DA Wolk JC Price JA Saxton BE Snitz JA James OL Lopez, et al. 2009 Amyloid imaging in mild cognitive impairment subtypes Ann Neurol 65 557 568 19475670 10.1002/ana.21598
34. KE Pike G Savage VL Villemagne S Ng SA Moss P Maruff, et al. 2007 Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease Brain J Neurol 130 2837 2844 10.1093/brain/awm238
35. J Koivunen N Scheinin JR Virta S Aalto T Vahlberg K Nagren, et al. 2011 Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study Neurology 76 1085 1090 21325653 10.1212/WNL.0b013e318212015e 1:STN:280:DC%2BC3M3ot1Klsg%3D%3D
36. WJ Jagust D Bandy K Chen NL Foster SM Landau CA Mathis, et al. 2010 The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement 6 221 229 20451870 10.1016/j.jalz.2010.03.003
37. CC Rowe KA Ellis M Rimajova P Bourgeat KE Pike G Jones, et al. 2010 Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 1275 1283 20472326 10.1016/j. neurobiolaging.2010.04.007
38. VL Villemagne KE Pike G Chetelat KA Ellis RS Mulligan P Bourgeat, et al. 2011 Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease Ann Neurol 69 181 192 21280088 10.1002/ana.22248 1:CAS:528: DC%2BC3MXisVCisLs%3D
39. A Forsberg O Almkvist H Engler A Wall B Langstrom A Nordberg 2010 High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters Curr Alzheimer Res 7 56 66 20205671 10.2174/156720510790274446 1:CAS:528:DC%2BC3cXisVGqtbY%3D
40. HJ Aizenstein RD Nebes JA Saxton JC Price CA Mathis ND Tsopelas, et al. 2008 Frequent amyloid deposition without significant cognitive impairment among the elderly Arch Neurol 65 1509 1517 19001171 10.1001/archneur.65.11.1509
41. CC Rowe S Ng U Ackermann SJ Gong K Pike G Savage, et al. 2007 Imaging beta-amyloid burden in aging and dementia Neurology 68 1718 1725 17502554 10.1212/01.wnl.0000261919.22630.ea 1:CAS:528:DC%2BD2sXltVSmsL0%3D
42. H Engler A Forsberg O Almkvist G Blomquist E Larsson I Savitcheva, et al. 2006 Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain J Neurol 129 2856 2866 10.1093/brain/awl178
43. NM Scheinin S Aalto J Koikkalainen J Lotjonen M Karrasch N Kemppainen, et al. 2009 Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls Neurology 73 1186 1192 19726751 10.1212/WNL.0b013e3181bacf1b 1:CAS:528:DC%2BD1MXht1antrfM
44. A Okello J Koivunen P Edison HA Archer FE Turkheimer K Nagren, et al. 2009 Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 73 754 760 19587325 10.1212/WNL.0b013e3181b23564 1:CAS:528:DC%2BD1MXhtVKrsbvF
45. EM Reiman K Chen X Liu D Bandy M Yu W Lee, et al. 2009 Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 106 6820 6825 19346482 10.1073/pnas.0900345106 1:CAS:528:DC%2BD1MXlsV2kt7Y%3D
46. JL Price JC Morris 1999 Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann Neurol 45 358 368 10072051 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X 1:STN:280:DyaK1M7ntValtQ%3D%3D
47. KM Rodrigue KM Kennedy MD Devous Sr JR Rieck AC Hebrank R Diaz-Arrastia, et al. 2012 β-Amyloid burden in healthy aging: regional distribution and cognitive consequences Neurology 78 387 395 22302550 10.1212/WNL. 0b013e318245d295 1:CAS:528:DC%2BC38XitVSlurc%3D
48. K Ritchie AM Dupuy 1999 The current status of apo E4 as a risk factor for Alzheimer's disease: an epidemiological perspective Int J Geriatr Psychiatry 14 695 700 10479739 10.1002/(SICI)1099-1166(199909)14:9<695::AID-GPS19>3.0. CO;2-R 1:STN:280:DyaK1MvhtVKnsA%3D%3D
49. Q Jiang CY Lee S Mandrekar B Wilkinson P Cramer N Zelcer, et al. 2008 ApoE promotes the proteolytic degradation of Abeta Neuron 58 681 693 18549781 10.1016/j.neuron.2008.04.010 1:CAS:528:DC%2BD1cXnvVSqsbY%3D
50. DE Schmechel AM Saunders WJ Strittmatter BJ Crain CM Hulette SH Joo, et al. 1993 Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease Proc Natl Acad Sci U S A 90 9649 9653 8415756 10.1073/pnas.90.20.9649 1:CAS:528:DyaK2cXmtFel
51. T Polvikoski R Sulkava M Haltia K Kainulainen A Vuorio A Verkkoniemi, et al. 1995 Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein N Engl J Med 333 1242 1247 7566000 10.1056/NEJM199511093331902 1:STN:280:DyaK28%2Fit1WgsQ%3D%3D
52. RC Petersen SC Waring GE Smith EG Tangalos SN Thibodeau 1996 Predictive value of APOE genotyping in incipient Alzheimer's disease Ann N Y Acad Sci 802 58 69 8993485 10.1111/j.1749-6632.1996.tb32599.x 1:STN:280:DyaK2s7ks1Khuw%3D%3D
53. JC Morris CM Roe C Xiong AM Fagan AM Goate DM Holtzman, et al. 2010 APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging Ann Neurol 67 122 131 20186853 10.1002/ana.21843 1:CAS:528: DC%2BC3cXksVGgu7c%3D
54. LS Elias-Sonnenschein W Viechtbauer IH Ramakers FR Verhey PJ Visser 2011 Predictive value of APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis J Neurol Neurosurg Psychiatry 82 1149 1156 21493755 10.1136/jnnp.2010.231555
55. CR Jack Jr VJ Lowe ML Senjem SD Weigand BJ Kemp MM Shiung, et al. 2008 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain J Neurol 131 665 680 10.1093/brain/awm336
56. MA Mintun GN Larossa YI Sheline CS Dence SY Lee RH Mach, et al. 2006 [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 67 446 452 16894106 10.1212/01.wnl.0000228230.26044.a4 1:STN:280:DC%2BD28vntVyisQ%3D%3D
57. M Storandt MA Mintun D Head JC Morris 2009 Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition Arch Neurol 66 1476 1481 20008651 10.1001/archneurol.2009.272
58. KE Pike KA Ellis VL Villemagne N Good G Chetelat D Ames, et al. 2011 Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study Neuropsychologia 49 2384 2390 21529702 10.1016/j.neuropsychologia. 2011.04.012
59. VL Villemagne MT Fodero-Tavoletti KE Pike R Cappai CL Masters CC Rowe 2008 The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias Mol Neurobiol 38 1 15 18690556 10.1007/s12035-008-8019-y 1:CAS:528:DC%2BD1cXhtVSgtLrJ
60. VL Villemagne KE Pike D Darby P Maruff G Savage S Ng, et al. 2008 Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease Neuropsychologia 46 1688 1697 18343463 10.1016/j.neuropsychologia.2008.02.008 1:STN:280:DC%2BD1cvivVKmtQ%3D%3D
61. GB Frisoni NC Fox CR Jack Jr P Scheltens PM Thompson 2010 The clinical use of structural MRI in Alzheimer disease Nat Rev Neurol 6 67 77 20139996 10.1038/nrneurol.2009.215
62. DM Rentz JJ Locascio JA Becker EK Moran E Eng RL Buckner, et al. 2010 Cognition, reserve, and amyloid deposition in normal aging Ann Neurol 67 353 364 20373347 10.1001/archneurol.2010.19
63. N Tolboom M Yaqub WM van der Flier R Boellaard G Luurtsema AD Windhorst, et al. 2009 Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET J Nucl Med 50 191 197 19164243 10.2967/jnumed.108.056499
64. G Chételat VL Villemagne KE Pike KA Ellis P Bourgeat G Jones, et al. 2011 Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease Brain J Neurol 134 798 807 10.1093/brain/awq383
65. S Nyberg ME Jonhagen Z Cselenyi C Halldin P Julin H Olsson, et al. 2009 Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184 Eur J Nucl Med Mol Imaging 36 1859 1863 19495746 10.1007/s00259-009-1182-1
66. Y Kudo N Okamura S Furumoto M Tashiro K Furukawa M Maruyama, et al. 2007 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients J Nucl Med 48 553 561 17401091 10.2967/jnumed.106.037556 1:CAS:528:DC%2BD2sXhtVert7nP
67. NP Verhoeff AA Wilson S Takeshita L Trop D Hussey K Singh, et al. 2004 In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET Am J Geriatr Psychiatry 12 584 595 15545326
68. J Shin SY Lee SJ Kim SH Kim SJ Cho YB Kim 2010 Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG Neuroimage 52 488 496 20385246 10.1016/j.neuroimage.2010.04.013
69. K Shoghi-Jadid GW Small ED Agdeppa V Kepe LM Ercoli P Siddarth, et al. 2002 Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease Am J Geriatr Psychiatry 10 24 35 11790632
70. GW Small V Kepe LM Ercoli P Siddarth SY Bookheimer KJ Miller, et al. 2006 PET of brain amyloid and tau in mild cognitive impairment N Engl J Med 355 2652 2663 17182990 10.1056/NEJMoa054625 1:CAS:528:DC%2BD28XhtlGhtLvL
71. ED Agdeppa V Kepe A Petri N Satyamurthy J Liu SC Huang, et al. 2003 In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malono nitrile Neuroscience 117 723 730 12617976 10.1016/S0306-4522(02)00907-7 1:CAS:528:DC%2BD3sXhs1KhsrY%3D
72. HF Kung SR Choi W Qu W Zhang D Skovronsky 2010 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective J Med Chem 53 933 941 19845387 10.1021/jm901039z 1:CAS:528:DC%2BD1MXht12hs7%2FM
73. N Nelissen K Van Laere L Thurfjell R Owenius M Vandenbulcke M Koole, et al. 2009 Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease J Nucl Med 50 1251 1259 19617318 10.2967/jnumed.109.063305 1:CAS:528:DC%2BD1MXhtVymtrrJ
74. R Vandenberghe K Van Laere A Ivanoiu E Salmon C Bastin E Triau, et al. 2010 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann Neurol 68 319 329 20687209 10.1002/ana.22068
75. CC Rowe U Ackerman W Browne R Mulligan KL Pike G O'Keefe, et al. 2008 Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism Lancet Neurol 7 129 135 18191617 10.1016/S1474- 4422(08)70001-2 1:CAS:528:DC%2BD1cXis1WmsLw%3D
76. VL Villemagne K Ong RS Mulligan G Holl S Pejoska G Jones, et al. 2011 Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias J Nucl Med 52 1210 1217 21764791 10.2967/jnumed.111.089730
77. DF Wong PB Rosenberg Y Zhou A Kumar V Raymont HT Ravert, et al. 2010 In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18) J Nucl Med 51 913 920 20501908 10.2967/jnumed.109.069088 1:CAS:528:DC%2BC3cXosl2ksb4%3D
78. AS Fleisher K Chen X Liu A Roontiva P Thiyyagura N Ayutyanont, et al. 2011 Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease Arch Neurol 68 1404 1411 21747008 10.1001/archneurol.2011.150
79. Thurfjell L, Lotjonen J, Lundqvist R, Koikkalainen J, Soininen H, Waldemar G, et al. Combination of biomarkers: PET [F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment. Neurodegener Dis. 2012. doi: 10.1159/000335381
80. LM Ercoli P Siddarth JR Barrio GW Small 2010 Response to Letter from Shin and Lee, entitled "FDDNP PET patterns in nondemented populations" Am J Geriatr Psychiatry 2 188 21552388 10.1097/JGP.0b013e3181c53339
81. Wilks M, Siddarth P, Ercoli L, Kepe V, Small G, Barrio J, et al. Longitudinal study of changes in FDDNP-PET and neuropsychological scores. J Nucl Med. 2011;52 suppl 1, abstract 1266.
82. J Shin SY Lee SH Kim YB Kim SJ Cho 2008 Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease Neuroimage 43 236 244 18694837 10.1016/j.neuroimage.2008.07.022
83. G Lucignani 2009 Clinical applications of PET amyloid imaging: an update Eur J Nucl Med Mol Imaging 36 1185 1190 19407998 10.1007/s00259-009-1148-3
84. 18F-florbetaben. Alzheimers Dement. 2011;7 suppl 1:S32.
85. Doraiswamy P, Clark C, Sperling R, Reiman E, Pontecorvo M, Sabbagh M, et al. Prognostic significance of florbetapir F18 PET imaging in MCI and normal elderly: final results from a longitudinal multicenter trial. Alzheimers Dement. 2011;7 suppl 1:S107.
86. CC Rowe VL Villemagne 2011 Brain amyloid imaging J Nucl Med 52 1733 1740 21917849 10.2967/jnumed.110.076315 1:CAS:528:DC%2BC3MXhs1ejtbbE
87. CM Clark C Davatzikos A Borthakur A Newberg S Leight VM Lee, et al. 2008 Biomarkers for early detection of Alzheimer pathology Neurosignals 16 11 18 18097155 10.1159/000109754 1:CAS:528:DC%2BD1cXhs1Wns70%3D
88. M Tobias LC Yeh E Johnson 2008 Burden of Alzheimer's disease: population-based estimates and projections for New Zealand, 2006-2031 Aust N Z J Psychiatry 42 828 836 18696288 10.1080/00048670802277297
89. JL Cummings G Cole 2002 Alzheimer disease JAMA 287 2335 2338 11988038 10.1001/jama.287.18.2335 1:CAS:528:DC%2BD38XjsVynsb4%3D